PLoS ONE (Jan 2012)

Association of the innate immunity and inflammation pathway with advanced prostate cancer risk.

  • Rémi Kazma,
  • Joel A Mefford,
  • Iona Cheng,
  • Sarah J Plummer,
  • Albert M Levin,
  • Benjamin A Rybicki,
  • Graham Casey,
  • John S Witte

DOI
https://doi.org/10.1371/journal.pone.0051680
Journal volume & issue
Vol. 7, no. 12
p. e51680

Abstract

Read online

Prostate cancer is the most frequent and second most lethal cancer in men in the United States. Innate immunity and inflammation may increase the risk of prostate cancer. To determine the role of innate immunity and inflammation in advanced prostate cancer, we investigated the association of 320 single nucleotide polymorphisms, located in 46 genes involved in this pathway, with disease risk using 494 cases with advanced disease and 536 controls from Cleveland, Ohio. Taken together, the whole pathway was associated with advanced prostate cancer risk (P = 0.02). Two sub-pathways (intracellular antiviral molecules and extracellular pattern recognition) and four genes in these sub-pathways (TLR1, TLR6, OAS1, and OAS2) were nominally associated with advanced prostate cancer risk and harbor several SNPs nominally associated with advanced prostate cancer risk. Our results suggest that the innate immunity and inflammation pathway may play a modest role in the etiology of advanced prostate cancer through multiple small effects.